A consumer survey has highlighted a major increase in the use of Pregabalin, an authorised antiepileptic drug. The working hypothesis is that this drug is being used in other pathologies, such as to treat neuropathic pain. What sort of indicators could we use to obtain information that might enable us to test this hypothesis?

Select one:

a.

The conducting of a controlled clinical trial enabling us to assess the efficacy of Pregabalin in neuropathic pain.

b.

The construction of drug-indication indicators (studying consumption in terms of the indication for which it is prescribed).

c.

The construction of indicators that relate the drug to the indication and the treatment outcome.

d.

A comparison between the consumption of Pregabalin in defined daily doses per 1000 inhabitants per day and the diagnosed prevalence of epilepsy.